Bleakley Financial Group LLC Invests $231,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bleakley Financial Group LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,108 shares of the medical equipment provider’s stock, valued at approximately $231,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LNTH. Swedbank AB raised its position in shares of Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after purchasing an additional 125,843 shares during the last quarter. Ulland Investment Advisors LLC increased its stake in Lantheus by 4.4% during the 3rd quarter. Ulland Investment Advisors LLC now owns 8,780 shares of the medical equipment provider’s stock valued at $964,000 after purchasing an additional 374 shares in the last quarter. Creative Planning raised its holdings in shares of Lantheus by 5.4% in the third quarter. Creative Planning now owns 24,988 shares of the medical equipment provider’s stock worth $2,742,000 after buying an additional 1,274 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Lantheus during the third quarter worth $51,000. Finally, Procyon Advisors LLC grew its holdings in shares of Lantheus by 16.0% during the third quarter. Procyon Advisors LLC now owns 3,252 shares of the medical equipment provider’s stock valued at $357,000 after buying an additional 449 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $110.64 on Thursday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company’s fifty day moving average price is $106.72 and its 200 day moving average price is $92.23. The company has a market capitalization of $7.67 billion, a PE ratio of 16.89 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus’s revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the business earned $1.40 earnings per share. On average, research analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. JMP Securities lowered their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. B. Riley lifted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Truist Financial cut their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 10,481 shares of Lantheus stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the sale, the director now owns 454,923 shares of the company’s stock, valued at approximately $43,445,146.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 10,481 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the sale, the director now owns 454,923 shares of the company’s stock, valued at approximately $43,445,146.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,981 shares of company stock valued at $2,689,156 in the last three months. 1.50% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.